Is Torrent Pharmaceuticals (TORNTPHARM) overvalued or fairly valued?

MarketChacha shows Torrent Pharmaceuticals's valuation in context — a forward P/E of about 53.3, a price-to-book of about 20.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Torrent Pharmaceuticals's revenue?

Torrent Pharmaceuticals reported revenue of ₹13,980 Cr for FY2026, with net profit of ₹2,163 Cr, per official filings.

What is the share price of Torrent Pharmaceuticals (TORNTPHARM)?

Torrent Pharmaceuticals last traded at ₹4,990.90 (+4.8% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Torrent Pharmaceuticals

TORNTPHARM · NSE · Pharma · India

₹4,990.90+4.8%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:38 AM

Snapshot

TickerTORNTPHARM

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees18,258

HeadquartersAhmedabad, India

Market cap₹1,69,405 Cr

P/B20.2

Volume1L

Websitewww.torrentpharma.com

Filings tracked0

About Torrent Pharmaceuticals

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Profile as reported by Yahoo Finance.

Who owns it

Promoters71.2%
Institutions15.8%
Public & other13.0%

238 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend12.9% → 15.5%

Margin has expanded by about 2.5 points — the business is getting more profitable.

Growth qualityrev 13% · PAT 20%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹4,824 Cr · EPS 14.51

Est. earnings growth -18.3%

Next fiscal year

Rev ₹21,406 Cr · EPS 93.95

Est. earnings growth +36.4%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹3,468.0052-wk range₹5,085.80

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹1,69,405 Cr

Day change

+4.8%

Fwd P/E

53.3

P/B

20.2

Div yield

0.80%

Beta

0.14

Revenue (FY2026)

₹13,980 Cr

Net margin

15.5%

Revenue CAGR (3y)

+13.3%

Profit CAGR (3y)

+20.2%

Net profit (FY2026)

₹2,163 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about TORNTPHARM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹13,980 Cr	₹2,163 Cr	15.5%
FY2025	₹11,516 Cr	₹1,911 Cr	16.6%
FY2024	₹10,728 Cr	₹1,656 Cr	15.4%
FY2023	₹9,620 Cr	₹1,245 Cr	12.9%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹4,197 Cr	₹389 Cr	9.3%
2025Q4	₹3,303 Cr	₹635 Cr	19.2%
2025Q3	₹3,302 Cr	₹591 Cr	17.9%
2025Q2	₹3,178 Cr	₹548 Cr	17.2%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.